Yan Meng

Yan Meng

Auto-generated profile, based on publicly available information

Yan Meng

Department of Anesthesiology, the First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, People's Republic of China

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2025 in Drug Design, Development and Therapy
Verified
Journal Article
Open access
PDF file
HZHongrui Zhu
Hongrui Zhu
ZWZaibao Wang
Zaibao Wang
SDSheng Ding
Sheng Ding
CLChunliu Li
Chunliu Li
LXLi Xie
Li Xie
SWSheng Wang
Sheng Wang
Objective: This study aimed to compare the effects of fospropofol disodium and propofol on perioperative neurocognitive function in elderly patients undergoing total hip arthroplasty (THA), evaluating the non-inferiority of fospropofol disodium in preventing or reducing perioperative neurocognitive disorders (PND) and exploring optimal clinical anesthesia strategies. Methods: A total of 180 elderly patients (aged 65~80 years) scheduled for THA between November 2022 and November 2024 were randomly assigned to the fospropofol disodium group (Group F, n=90) or the propofol group (Group P, n=90). Cognitive function was assessed preoperatively (1 day before surgery) and postoperatively (1, 3, 7 days, and 1 month) using the Modified Mini-Mental State Examination (MMSE), 3-Minute Diagnostic Interview for Confusion Assessment Method (3D-CAM), Digit Span Test (DST), Verbal Fluency Test (VFT), and Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE). The incidence of postoperative cognitive dysfunction (POCD) and delirium (POD), hemodynamic parameters, and adverse events were compared between the two groups. Results: No significant differences were observed between the two groups in the incidence of POCD (p> 0.05) or POD (p> 0.05) at any postoperative time point. At the time point of 10 minutes after bone cement implantation (T4), the heart rate of patients in the Group F was higher than that of Group P (p < 0.0001). At the time of discharge from the PACU, the heart rate of patients in the Group F was lower than that of the Group P (p = 0.037). Group F exhibited higher mean arterial pressure (MAP) at the beginning of the operation (p=0.022) and a longer extubation time and waking time (p < 0.001) but had significantly lower incidences of injection pain (p=0.018) and postoperative nausea and vomiting (p=0.037). Binary logistic regression identified age as an independent risk factor for PND [OR=1.149, p=0.006], while preoperative MMSE score was a protective factor [OR=0.693, p = 0.002]. Conclusion: Fospropofol disodium may be a viable alternative in settings where injection pain and PONV are primary concerns, provided that hemodynamic stability is actively managed in elderly THA patients, with non-inferior efficacy in preventing PND compared to propofol and fewer adverse effects. Age and preoperative cognitive function are critical predictors of PND, warranting careful consideration in perioperative management.

1 September 2025 in Drug Design, Development and Therapy
Verified
Journal Article
Open access
PDF file
MXMin Xu
Min Xu
SWSheng Wang
Sheng Wang
YMYan Meng
Yan Meng
CGChen Gao
Chen Gao
LLLin Liu
Lin Liu
KHKeqiang He
Keqiang He
Purpose: This study aimed to compare the analgesic efficacy of liposomal bupivacaine with that of traditional ropivacaine in adductor canal blocks for patients undergoing knee arthroplasty. Patients and Methods: A total of 119 consenting participants, who were scheduled for elective knee arthroplasty (including total knee replacement and unicompartmental knee replacement) under general anesthesia, were randomly assigned to either receive an ultrasound-guided adductor canal block with ropivacaine or liposomal bupivacaine. The primary endpoint of this study was the pain scores at 2, 24, 48, and 72 hours post-surgery. Secondary outcomes included nausea, vomiting, and pruritis, the ability to engage in physiotherapy on the first day after surgery, postoperative exercise, patient satisfaction with anesthesia, postoperative recovery index, and patient-controlled analgesic presses (12– 48 hours) for both groups. Results: The Visual Analog Scale (VAS), assessed from 24 to 72 hours post-follow-up, demonstrated that patients receiving ropivacaine had higher median VAS scores compared to those in the liposomal bupivacaine group, both at rest and during exercise. The weighted AUC numerical rating scale pain scores whether at rest or move in the liposomal bupivacaine group was lower than the standard bupivacaine group with statistical significance. Whether it is 0– 24 hours (Rest 58.00 [53.75, 69.00] vs 48.00 [46.50, 58.00]; Move:57.00 [46.00, 59.00] vs 36.00 [35.00, 48.00]) or 0– 72 hours (Rest 214.00 [197.75, 237.00] vs 165.00 [143.50, 180.00]; Move:202.00 [190.00, 215.75]vs.156.00 [131.00, 178.00]) From 12 to 48 hours, the ropivacaine group had a significantly higher number of PCIA presses. The liposomal bupivacaine group also achieved greater pain-free bending angles and walking distances compared to the ropivacaine group. Conclusion: Liposomal bupivacaine used in adductor canal block provides extended pain relief in knee arthroplasty patients, aiding early rehabilitation.

1 November 2025 in Drug Design, Development and Therapy
Verified
Journal Article
Open access
PDF file
YMYan Meng
Yan Meng
YSYouping Song
Youping Song
CGChen Gao
Chen Gao
SWSheng Wang
Sheng Wang
KHKeqiang He
Keqiang He
MXMin Xu
Min Xu
Background: Endoscopic Retrograde Cholangiopancreatography (ERCP) requires precise anesthesia control. Remimazolam is ideal for induction due to its rapid onset and minimal cardiorespiratory impact, but its optimal dose across ages is unclear. This study determined the median effective dose (ED50) of remimazolam for ERCP induction and assessed the influence of age. Methods: In this prospective study, 110 patients aged 50– 89 years (ASA I–III, BMI 18– 30 kg/m2) scheduled for ERCP were stratified into four age groups: R1 (50– 59), R2 (60– 69), R3 (70– 79), and R4 (80– 89). The Dixon up-and-down method was used, with the initial dose for R1 set at 0.1 mg/kg remimazolam and sequentially reduced by 0.01 mg/kg for the first patient in each older group. Patients received 0.1 μg/kg sufentanil prior to the intravenous administration of a predetermined dose of remimazolam. Anesthesia success was defined as a Modified Observer’s Assessment of Alertness/Sedation (MOAA/S) score of 0 at 3 minutes after intravenous remimazolam administration, which served as the endpoint for determining the effective induction dose. Results: To determine the effective dose for inducing anesthesia, the ED50 of remimazolam were calculated for groups R1 to R4 as follows: 0.122, 0.108, 0.093, and 0.078 mg/kg, respectively. Similarly, the dosage required to achieve ED95 for the same groups was determined to be 0.132, 0.122, 0.113, and 0.090 mg/kg.Bivariate and multivariable linear regression analyses confirmed a significant inverse correlation between age and remimazolam dose requirement (r = − 0.829, p < 0.001), with age remaining an independent predictor after adjusting for confounders. Conclusion: This study confirms a significant and independent inverse correlation between age and the required induction dose of remimazolam for ERCP. The ED50 decreases progressively with advancing age. We recommend a tailored reduction in the remimazolam induction dose for geriatric patients to enhance safety.